Idorsia Ltd. (IDRSF)
5.38
0.00 (0.00%)
USD |
OTCM |
Oct 09, 16:00
Idorsia Free Cash Flow (Quarterly) : -46.53M for June 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -46.53M |
| March 31, 2026 | -36.05M |
| December 31, 2025 | -58.02M |
| September 30, 2025 | -31.83M |
| June 30, 2025 | -64.26M |
| March 31, 2025 | -74.45M |
| December 31, 2024 | -7.955M |
| September 30, 2024 | -115.22M |
| June 30, 2024 | -124.35M |
| March 31, 2024 | -136.18M |
| December 31, 2023 | -126.12M |
| September 30, 2023 | -88.38M |
| June 30, 2023 | -217.02M |
| March 31, 2023 | -274.14M |
| December 31, 2022 | -232.98M |
| September 30, 2022 | -207.90M |
| June 30, 2022 | -217.09M |
| March 31, 2022 | -271.72M |
| December 31, 2021 | -223.39M |
| Date | Value |
|---|---|
| September 30, 2021 | -132.84M |
| June 30, 2021 | -154.00M |
| March 31, 2021 | -168.53M |
| December 31, 2020 | -140.56M |
| September 30, 2020 | -101.56M |
| June 30, 2020 | -47.29M |
| March 31, 2020 | -111.45M |
| December 31, 2019 | -133.18M |
| September 30, 2019 | -133.57M |
| June 30, 2019 | -106.34M |
| March 31, 2019 | -111.22M |
| December 31, 2018 | -130.21M |
| September 30, 2018 | -98.92M |
| June 30, 2018 | -67.52M |
| March 31, 2018 | -77.53M |
| December 31, 2017 | 140.99M |
| September 30, 2017 | -57.65M |
| June 30, 2017 | 106.54M |
| March 31, 2017 | -100.31M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| BeOne Medicines Ltd. | 436.10M |
| AC Immune SA | -- |
| CRISPR Therapeutics AG | -84.15M |